People with severe COVID-19 could use Paxlovid to stop long-COVID

Embargoed until: Publicly released: 2023-03-24 02:00

International

Image by Gerd Altmann from Pixabay

For people with COVID-19 and at least one risk factor for progression to severe disease, treatment with the antiviral medication nirmatrelvir - otherwise known as Paxlovid - within five days of a positive COVID-19 test result was associated with reduced risk of developing long-COVID, according to international researchers, regardless of vaccination status or history of prior infection.

Media release

From: JAMA

About The Study: This cohort study found that in people with SARS-CoV-2 infection who had at least one risk factor for progression to severe disease, treatment with nirmatrelvir within five days of a positive SARS-CoV-2 test result was associated with reduced risk of post−COVID-19 condition (also known as long COVID) across the risk spectrum in this cohort and regardless of vaccination status and history of prior infection. The totality of the findings suggests that treatment with nirmatrelvir during the acute phase of COVID-19 may reduce the risk of post–acute adverse health outcomes.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page

Journal/
conference: JAMA Internal Medicine

Research:Paper

Organisation/s: VA St Louis Health Care System, USA

Funder: This study used data from the US Department of Veterans Affairs (VA) COVID-19 Shared Data Resource. This research was funded by the VA (Z.A.A.).

Media Contact/s

Contact details are only visible to registered journalists.